Table 3 Risk factor of major bleeding event in patients with chronic kidney disease receiving pentoxifylline.
From: The risk of major bleeding event in patients with chronic kidney disease on pentoxifylline treatment
CHR (95% CI) | AHR (95% CI) | P-value | |
|---|---|---|---|
Pentoxifylline | |||
< 800 mg/day | Ref. | Ref. | |
≥ 800 mg/day | 1.68 (1.11–2.52) | 1.73 (1.14–2.62) | 0.0095 |
Age group | |||
18–59 | Ref. | Ref. | |
60 ≥ | 1.55 (1.02–2.35) | 1.29 (0.83–2.01) | 0.2545 |
Gender | |||
Female | Ref. | Ref. | |
Male | 0.77 (0.5–1.15) | 0.68 (0.46–1.02) | 0.0599 |
Aspirin used | |||
No | Ref. | Ref. | |
Non-regular | 2.24 (1.39–3.61) | 1.80 (1.06–3.04) | 0.0291 |
Regular | 1.78 (0.91–3.46) | 1.42 (0.70–2.85) | 0.3319 |
Comorbidities (compared with no such comorbidity) | |||
DM | 1.38 (0.93–2.06) | 1.17 (0.77–1.77) | 0.4518 |
HTN | 1.34 (0.83–2.17) | 1.13 (0.69–1.85) | 0.6395 |
Hyperlipidaemia | 1.27 (0.86–1.89) | 1.35 (0.89–2.04) | 0.1552 |
Ischemia stroke | 2.10 (1.37–3.21) | 1.76 (1.12–2.75) | 0.0140 |
CAD | 1.43 (0.92–2.21) | 1.04 (0.65–1.68) | 0.8715 |
ESRD | 1.08 (0.34–3.40) | 1.37 (0.42–4.44) | 0.6011 |
DAPT/anticoagulants | 1.48 (0.90–2.44) | 1.23 (0.73–2.06) | 0.4322 |
